RYBREVANT 350MG INJECTION

Form: Injection

Pack Size: 1 VIAL

Marketed by: JOHNSON & JOHNSON (ONCOLOGY DIV)

MRP: ₹85075.89

JOHNSON & JOHNSON (ONCOLOGY DIV): Rybrevant 350MG Injection, 1 vial, salt amivantamab 350mg. Its MRP stays at Rs 85,075.89 in NPPA's 09-11-2026 anti-cancer trade-margin revision; trade rate Rs 64,819.73. Group: EGFR-MET bispecific antibody (targeted therapy). No other manufacturer of this salt and strength is listed here yet. Handling/counselling: IV infusion in hospital only; store at 2-8 C, do not freeze. Schedule H - supply only to licensed buyers and dispense only on prescription.

Available at wholesale price for chemists, retailers and distributors on WholesaleChemist.